ライフサイエンスコーパス: IHD

1 IHD (29.8%), CKD (24.5%) and stroke (16.0%) are the most

2 IHD in patients with T2DM had an especially negative inf

3 IHD risk by vegetarian status was estimated by using mul

4 IHD risks were estimated with multivariable Cox regressi

5 ncrement; 95% CI) of CVD (0.96; 0.85, 1.09), IHD (0.90; 0.81, 1.04), stroke (1.09; 0.86, 1.39), or HF

6 average follow-up of 11.6 y, there were 1235 IHD cases (1066 hospital admissions and 169 deaths).

7 We documented 1660 IHD deaths during 804,433 person-years of follow-up.

8 During 12 y of follow-up, 1807 IHD events occurred.

9 correlation [r]=0.62), indicating that the 2 IHD phenotypes had differing risk profiles.

10 ely 7 y of follow-up, 372 CVD deaths and 249 IHD deaths occurred.

11 occurred, including 396 CVD-related and 266 IHD-related deaths.

12 eimer's disease (1.17, 95% CI 0.96 to 1.43), IHD (0.96, 95% CI 0.80 to 1.14), lipids, glycemic traits

13 y (IQR: 9.9-10.8 y), a total of 641 CVD, 465 IHD, 172 stroke, and 265 HF events occurred.

14 A coal combustion PM2.5 IHD HR = 1.05 (95% CI: 1.02, 1.08) per microgram/cubic m

15 Overall, 23% had HFpEF (52% IHD), 21% had HFmrEF (61% IHD), and 55% had HFrEF (60% I

16 ticipants, 2673 all-cause, 1085 CVD, and 576 IHD deaths occurred (median follow-up, 14.5 years).

17 had HFmrEF (61% IHD), and 55% had HFrEF (60% IHD).

18 23% had HFpEF (52% IHD), 21% had HFmrEF (61% IHD), and 55% had HFrEF (60% IHD).

19 sed 313,041 individuals and 11,995 CVD, 7534 IHD, and 2686 fatal IHD events.

20 prised 501,791 unique individuals and 11,869 IHD, 8244 stroke, and 14,449 diabetes events.

21 idence of AMI (HR, 0.70; 95% CI, 0.52-0.93), IHD (HR, 0.88; 95% CI, 0.73-1.05), and autoimmune diseas

22 viruses, are directly associated with acute IHD-related events in older individuals.

23 on that TSH, FT4 or TPOAb positivity affects IHD, despite potential effects on its risk factors.

24 ectories of work disability before and after IHD and stroke events.

25 , 1.08) per microgram/cubic meter, versus an IHD HR = 1.01 (95% CI: 1.00, 1.02) per microgram/cubic m

26 VD mortality (HRs between 0.68 and 0.75) and IHD mortality (HRs between 0.55 and 0.70).

27 rease; 95% CI] of CVD (0.87; 0.78, 0.97) and IHD (0.86; 0.75, 0.97), as well as nonsignificant invers

28 oordination are critical elements of ACS and IHD control strategies.

29 s well as in access to treatment for ACS and IHD.

30 quately address the global burden of ACS and IHD.

31 ases, acute myocardial infarction (AMI), and IHD.

32 ween low-density lipoprotein cholesterol and IHD genetic load is more than multiplicative, supporting

33 and low-density lipoprotein cholesterol, and IHD to create GRSs for each factor.

34 decaffeinated, may lower the risk of CVD and IHD mortality in patients with a prior MI.

35 le of magnesium in the prevention of CVD and IHD.

36 the risk of cardiovascular disease (CVD) and IHD mortality when the sum of SFAs and trans fatty acids

37 d T2DM, depression, Alzheimer's disease, and IHD and its risk factors by genetically predicted coffee

38 ive protein and between the lipoproteins and IHD.

39 HRs for CVD mortality and IHD mortality for theoretical, isocaloric replacement of

40 Patients with both T2DM and IHD had the highest mortality, which was further accentu

41 in ischemic heart disease (IHD) we assessed IHD risk and risk factors according to genetically predi

42 On average, IHD deaths in South Asia, North Africa and the Middle Ea

43 rt Failure Registry with respect to baseline IHD, outcomes (IHD, HF, cardiovascular events, and all-c

44 iable adjustment, associations with baseline IHD were similar for HFmrEF and HFrEF and lower in HFpEF

45 ed significant positive associations between IHD and several UF components including EC, Cu, metals,

46 ed significant positive associations between IHD mortality and both fine and ultrafine particle speci

47 attenuated by a 25.3% decrease in per capita IHD burden (decreased rate).

48 CD34(+) percentage in patients with chronic IHD correlated with decrement in LVEF (-2.9% versus +0.7

49 us -0.02%; P=0.021 for patients with chronic IHD).

50 to define the risk profile of a contemporary IHD phenotype.

51 and dietary magnesium with incidence of CVD, IHD, and fatal IHD.

52 o-potassium excretion ratio and risk of CVD, IHD, stroke, or HF.

53 rs of follow-up, 3401 participants developed IHD and 1708 developed MI.

54 s of follow-up 13 945 participants developed IHD.

55 ients with CKD had higher risk of developing IHD (16.3%), stroke (8.9%) and all-cause mortality (8.7%

56 a higher risk (9.2% to 24.4%) of developing IHD or CKD, respectively.

57 , a 26% reduction in ischemic heart disease (IHD) (RR: 0.74; 95% CI: 0.63-0.88), a 32% reduction in s

58 = 5,818 deaths) for ischemic heart disease (IHD) after adjustment for dose fractionation.

59 mes of patients with ischemic heart disease (IHD) after ventricular tachycardia (VT) ablation.

60 ) is associated with ischemic heart disease (IHD) among organ transplant recipients.

61 e (ALT) levels with ischaemic heart disease (IHD) and cardiovascular disease (CVD) risk factors are i

62 e of birth weight in ischemic heart disease (IHD) and lipids.

63 ciate with and cause ischemic heart disease (IHD) and myocardial infarction (MI).

64 s is associated with ischemic heart disease (IHD) and related clinical events, sex-specific differenc

65 Ischemic heart disease (IHD) burden consists of years of life lost from IHD deat

66 e intake and risk of ischemic heart disease (IHD) has not been fully explored in Asian populations kn

67 agnesium and risk of ischemic heart disease (IHD) have yielded inconsistent results, in part because

68 e pathogenic role of ischemic heart disease (IHD) in heart failure (HF) with reduced ejection fractio

69 Recognition of ischemic heart disease (IHD) is often delayed or deferred in women.

70 Ischemic heart disease (IHD) is one of the leading causes of death worldwide.

71 Ischemic heart disease (IHD) is the greatest single cause of mortality and loss

72 Ischemic heart disease (IHD) is the leading cause of death worldwide.

73 ase (CVD) mortality, ischemic heart disease (IHD) mortality, and all-cause mortality in patients with

74 m PM2.5 exposure and ischemic heart disease (IHD) mortality, as established in the American Cancer So

75 Ischemic heart disease (IHD) occurred in 62% of patients with T2DM and 47% of th

76 -y incidence of CVD [ischemic heart disease (IHD) or stroke].

77 lity attributable to ischemic heart disease (IHD) require an understanding of the changing epidemiolo

78 ferences in incident ischemic heart disease (IHD) risk between vegetarians and nonvegetarians.

79 factor confluence on ischemic heart disease (IHD) risk by testing whether genetic risk scores (GRSs)

80 cid (SFA) intake and ischemic heart disease (IHD) risk is debated.

81 y leads to increased ischemic heart disease (IHD) risk, but the risk is thought to be mediated throug

82 e resulting risk for ischemic heart disease (IHD) using literature-derived dose-response values.

83 ngiography in stable ischemic heart disease (IHD) varies widely.

84 thyroid function in ischemic heart disease (IHD) we assessed IHD risk and risk factors according to

85 use, cardiovascular, ischemic heart disease (IHD), and respiratory mortality.

86 diovascular disease, ischemic heart disease (IHD), and stroke) in adult women.

87 toimmune disease and ischemic heart disease (IHD), as well as all-cause mortality.

88 ally associated with ischemic heart disease (IHD), but whether elevated nonfasting remnant cholestero

89 pital admissions for ischemic heart disease (IHD), congestive heart failure (CHF), and overall CVD we

90 farction (MI), other ischemic heart disease (IHD), congestive heart failure (CHF), stroke, chronic ki

91 o metabolic risks on ischemic heart disease (IHD), hypertensive heart disease (HHD), stroke, diabetes

92 VD), including fatal ischemic heart disease (IHD), is unclear.

93 sociate with risk of ischemic heart disease (IHD), myocardial infarction (MI), and death in the gener

94 cal model of chronic ischemic heart disease (IHD), myocardial ischemia and exertional angina are caus

95 legumes and risk of ischemic heart disease (IHD), stroke, and diabetes have not been well establishe

96 were CVD [including ischemic heart disease (IHD), stroke, and vascular interventions], IHD, stroke,

97 fluenza outbreaks to ischemic heart disease (IHD)-related events.

98 l and in relation to ischemic heart disease (IHD).

99 VM) in patients with ischemic heart disease (IHD).

100 with a lower risk of ischemic heart disease (IHD).

101 A) is independent of ischemic heart disease (IHD).

102 r's disease, but not ischemic heart disease (IHD).

103 ted patients without ischemic heart disease (IHD).

104 al infarction [MI], ischaemic heart disease [IHD], cardiomyopathy, and heart failure).

105 Ischemic and/or non-ischemic heart diseases (IHD and/or NIHD) were detected in 147 (86.5%), 13 (7.6%)

106 erative knowledge of intrahepatic bile duct (IHD) anatomy is critical for planning liver resections,

107 The EHR IHD phenotype was most strongly correlated with ARIC met

108 The EHR IHD risk profile differed from ARIC and indicates that t

109 es between the ARIC risk factors and the EHR IHD were modestly linearly correlated with hazards ratio

110 Established IHD was an important prognostic factor across all HF typ

111 ss-sectional approach, we compared estimated IHD mortality risks among neighborhoods based on "walkab

112 etween-neighborhood variability in estimated IHD mortality attributable to physical inactivity was mo

113 etween-neighborhood differences in estimated IHD mortality from air pollution were comparable in magn

114 Cox proportional hazard models, we estimated IHD mortality hazard ratios (HRs) for PM2.5, trace const

115 als and 11,995 CVD, 7534 IHD, and 2686 fatal IHD events.

116 IHD (RR: 0.83; 95% CI: 0.75, 1.05) and fatal IHD (RR: 0.61; 95% CI: 0.37, 1.00).

117 nesium with incidence of CVD, IHD, and fatal IHD.

118 of nuts was inversely associated with fatal IHD (6 studies; 6749 events; RR per 4 weekly 28.4-g serv

119 association of dietary magnesium with fatal IHD was nonlinear (P < 0.001), with an inverse associati

120 t with risk of incident (nonfatal and fatal) IHD.

121 HD deaths/100,000/year for PM2.5 and 3 fewer IHD deaths for O3 in high- vs. low-walkability neighborh

122 e to physical inactivity was modest (7 fewer IHD deaths/100,000/year in high- vs. low-walkability nei

123 CVD mortality, and 1.1 (95% CI, 0.7-2.0) for IHD mortality.

124 000 person-years ranged from 9.5 to 12.2 for IHD, 7.7 to 9.1 for CHF, and 15.8 to 19.2 for overall CV

125 in this age group were 1.18 (1.08-1.29) for IHD and 1.14 (1.01-1.29) for total stroke.

126 io estimate of 1.19 (95% CI: 1.08, 1.31) for IHD in association with a 10-mug/m3 increase in PM2.5 is

127 -2.63) for diabetes, to 1.44 (1.40-1.48) for IHD.

128 CVD mortality, and 3.7 (95% CI, 2.8-4.5) for IHD mortality.

129 1 mmol/L higher TC were 1.44 (1.29-1.61) for IHD and 1.20 (1.15-1.25) for ischemic stroke.

130 .40 (95% confidence interval, 1.20-1.62) for IHD and 1.57 (1.28-1.93) for MI, in individuals with 3 t

131 mortality, and 0.30 (95% CI, 0.13-0.68) for IHD mortality, comparing participants who met 6 or more

132 n rate per 100,000 person-years of 242.7 for IHD (P = 0.02), 271.8 for CHF (P = 0.01), and 497.2 for

133 CVD mortality, and 63% (95% CI, 5%-89%) for IHD mortality.

134 total cardiovascular death, 6 estimates for IHD, and 7 estimates for death from stroke.

135 iables interacted with statin use except for IHD (P=0.001), with a hazard ratio of 0.76 (95% confiden

136 (RR=1.16), and combined hospitalizations for IHD- and medically attended acute respiratory illness (M

137 the corresponding observed hazard ratio for IHD and MI by Cox regression was 1.18 (95% CI: 1.15 to 1

138 The estimated causal odds ratio for IHD and MI by instrumental variable analysis for a 1-mmo

139 Finally, the causal risk ratio for IHD for a 1-mmol/L (39-mg/dL) higher level was 3.3 (95%

140 The hazard ratio for IHD in subjects with nonfasting glucose levels >/=11 mmo

141 RRs for IHD-related hospitalizations (RR=1.06), deaths (RR=1.16)

142 Also, RRs for IHD-related hospitalizations each year were significantl

143 ly, for residents aged >/= 65 years, RRs for IHD-related hospitalizations each year were significantl

144 RRs for IHD-related hospitalizations increased significantly wit

145 HRs were similar for IHD mortality.

146 Sources for IHD mortality estimates were country-level surveillance,

147 ation between age at menarche and death from IHD was observed only among nonsmoking populations or po

148 sed radiation-associated risks of death from IHD, in particular, significantly increased radiation ri

149 Deaths from IHD and acute coronary syndrome (ACS) occur, on average,

150 ) burden consists of years of life lost from IHD deaths and years of disability lived with 3 nonfatal

151 About 32.4% of the growth in global IHD disability-adjusted life-years between 1990 and 2010

152 emic Heart Disease study, of whom 10 668 had IHD diagnosed between 1977 and 2011.

153 ral and environmental determinants of higher IHD mortality.

154 tes was significantly associated with higher IHD risks (HR per 5% of energy: 1.27-1.37).

155 er SFA intake was not associated with higher IHD risks.

156 apacity of risk factor confluence to improve IHD risk prediction is questionable.

157 days increased to 83.9 (95% CI 80.6-86.5) in IHD; to 179.5 (95% CI 172.4-186.8) in stroke, a six-fold

158 or, has been shown to reduce LV afterload in IHD and may therefore also regress LVH.

159 nt inverse dose-fractionation association in IHD mortality requires further investigation.

160 2.4-186.8) in stroke, a six-fold increase in IHD and 14-fold in stroke.

161 l traffic, were associated with increases in IHD mortality in this nationwide population.

162 nt decreases close to the pre-event level in IHD but remains particularly high after stroke; among pa

163 Post-ban reductions in IHD, stroke, and COPD mortalities were seen in ages >/=6

164 ssociations between eating nuts and incident IHD and diabetes and eating legumes and incident IHD.

165 and diabetes and eating legumes and incident IHD.

166 ed with hazards ratio estimates for incident IHD in ARIC (Pearson correlation [r]=0.62), indicating t

167 IgG antibody levels are related to incident IHD compared to seronegativity.

168 of nut and legume consumption with incident IHD, stroke, and diabetes.

169 The increased IHD risk because of obesity was partly mediated through

170 The increased IHD risk caused by obesity was partly mediated through e

171 (IHD), stroke, and vascular interventions], IHD, stroke, and new-onset heart failure (HF).

172 In the 310 participants with known IHD (18% women, 82% men), most baseline characteristics

173 vary greatly by source, and that the largest IHD health benefits per microgram/cubic meter from PM2.5

174 Total SFA intake was associated with a lower IHD risk (HR per 5% of energy: 0.83; 95% CI: 0.74, 0.93)

175 Slightly lower IHD risks were observed for higher intakes of the sum of

176 The lower IHD risk observed did not depend on the substituting mac

177 a vegetarian diet was associated with lower IHD risk, a finding that is probably mediated by differe

178 More IHD deaths occurred in South Asia in 2010 than in any ot

179 llution were comparable in magnitude (9 more IHD deaths/100,000/year for PM2.5 and 3 fewer IHD deaths

180 New IHD (n = 13521) and stroke (n = 7162) cases in 2006-2008

181 prevalence of IHD and a greater risk of new IHD events.

182 Those with IHD, particularly new IHD events, were also more likely to change to a lower E

183 6; 95% CI: 0.69, 0.84; I(2) = 28%), nonfatal IHD (4 studies; 2101 events; RR: 0.78; 0.67, 0.92; I(2)

184 nd years of disability lived with 3 nonfatal IHD sequelae: nonfatal acute myocardial infarction, angi

185 had an increased risk of fatal and nonfatal IHD (multivariable HR: 1.60; 95% CI: 1.28, 2.00) compare

186 y (IQR: 9.9-10.8 y), 462 fatal and nonfatal IHD events occurred.

187 ecreased age-standardized fatal and nonfatal IHD in most regions since 1990, population growth and ag

188 The number of people living with nonfatal IHD increased more than the number of IHD deaths since 1

189 lower risk (HR: 0.68; 95% CI: 0.58, 0.81) of IHD than did nonvegetarians, which was only slightly att

190 number of IHD deaths since 1990, but >90% of IHD disability-adjusted life-years in 2010 were attribut

191 cally significant (p < 0.05) associations of IHD with PM2.5 mass, nitrate, elemental carbon (EC), cop

192 o estimate the global and regional burden of IHD in 1990 and 2010.

193 h and aging led to a higher global burden of IHD in 2010.

194 The global burden of IHD increased by 29 million disability-adjusted life-yea

195 Incident cases of IHD were identified through linkage with hospital record

196 concept of nonobstructive CAD as a cause of IHD and related adverse outcomes among women.

197 ,885 individuals aged 20 to 93 years free of IHD were followed from 1976 through 1978 until June 2011

198 rotic plaque, and the clinical management of IHD is centered on the identification and removal of the

199 lidation process led to an ensemble model of IHD mortality for 21 world regions.

200 nfatal IHD increased more than the number of IHD deaths since 1990, but >90% of IHD disability-adjust

201 T cells prior to challenge with 10(4) PFU of IHD-J-Luc and treated with BCV postchallenge survived th

202 , and survived rechallenge with 10(5) PFU of IHD-J-Luc VACV without additional BCV treatment.

203 y sex, age, BMI, smoking, or the presence of IHD risk factors.

204 F or nonischemic HF based on the presence of IHD) was assessed through registry linkages.

205 cted mortality regardless of the presence of IHD, with adjusted hazard ratios (HRs) and 95% confidenc

206 ed outcomes, specifically in the presence of IHD.

207 F with regard to both a higher prevalence of IHD and a greater risk of new IHD events.

208 a outbreak periods (intense-IOP) to rates of IHD-related hospitalizations and deaths for Maryland res

209 rth weight was associated with lower risk of IHD (odds ratio (OR) 0.96 per 100 grams, 95% confidence

210 but was associated with a 22% lower risk of IHD (RR: 0.78; 95% CI: 0.67, 0.92).

211 Risk of IHD and MI increased stepwise with increasing nonfasting

212 The risk of IHD and MI increased stepwise with increasing number of

213 both women and men, absolute 10-year risk of IHD and MI increased with increasing number of visible a

214 lymorphisms associate with increased risk of IHD and MI.

215 ng glucose levels and with increased risk of IHD and MI.

216 ole grains was associated with lower risk of IHD death.

217 %, -1.29%) was associated with lower risk of IHD death.

218 nt IHD was associated with increased risk of IHD events and all other outcomes in all EF categories e

219 The adjusted risk of IHD events was similar for HFmrEF versus HFrEF and lower

220 es that explained the highest excess risk of IHD from genetically determined obesity were low-density

221 dependently associated with a higher risk of IHD incidence.

222 , 1.14)] and fiber intake with lower risk of IHD mortality [men: 0.94 (95% CI: 0.82, 1.08); women: 0.

223 asmata was associated with increased risk of IHD or MI after multifactorial adjustment for chronologi

224 cose levels associate with increased risk of IHD, but whether this is also true for nonfasting levels

225 ization suggest that ALT reduces the risk of IHD, probably through reducing triglyceride levels.

226 d remnant cholesterol with 7% excess risk of IHD.

227 ed between circulating magnesium and risk of IHD.

228 urinary magnesium, could reduce the risk of IHD.

229 nnot be explained by their increased risk of IHD.

230 0.2 mmol/L) and trends toward lower risks of IHD (RR: 0.83; 95% CI: 0.75, 1.05) and fatal IHD (RR: 0.

231 Radiation-related risks of IHD decreased significantly with increasing time since f

232 dose fractionation effect in dose trends of IHD was observed, with the highest estimate of ERR/Gy fo

233 g features of various anatomical variants of IHD using magnetic resonance cholangio-pancreatography (

234 onship may present an oversimplified view of IHD.

235 genetic risk load has an additive effect on IHD risk.

236 ith more generalized inclusion or focused on IHD may be warranted.

237 ng evidence for an effect of birth weight on IHD and lipids.

238 is to estimate the effect of birth weight on IHD using the CARDIoGRAMplusC4D 1000 Genomes based GWAS

239 troke in patients with a prior MI (10.8%) or IHD (8.9%).

240 stry with respect to baseline IHD, outcomes (IHD, HF, cardiovascular events, and all-cause death), an

241 ions provide additional value for predicting IHD risk.

242 After adjustment, prevalent IHD was associated with increased risk of IHD events and

243 a control group of patients without previous IHD undergoing similar surgical procedures (n = 20,232).

244 fter intranasal infection with a recombinant IHD-J-Luc VACV expressing luciferase.

245 tranasal route with 10(5) PFU of recombinant IHD-J-Luc VACV expressing luciferase.

246 ies 2010 Study estimated global and regional IHD mortality from 1980 to 2010.

247 gly positively associated with self-reported IHD, systolic and diastolic blood pressure, low-density

248 ck of recognition is related to sex-specific IHD pathophysiology that differs from traditional models

249 Patients with stable IHD enrolled in the REMIT (Responses of Mental Stress-In

250 between male and female patients with stable IHD.

251 Globally, age-standardized IHD mortality has declined since the 1980s, and high-inc

252 High age-standardized IHD mortality in Eastern Europe, Central Asia, and South

253 Age-standardized IHD mortality increased in former Soviet Union countries

254 rly in high-income regions, age-standardized IHD mortality rates have declined significantly since 19

255 entral Asia had the highest age-standardized IHD mortality rates.

256 d, a large number of studies have found that IHD can occur in the presence or absence of obstructive

257 Work disability leveled off among the IHD cases but not among those who had stroke.

258 t differences in disability days between the IHD and stroke cases and five years prior to the event,

259 gle amino acid substitutions at D1416 in the IHD motif (isoleucine-histidine-aspartic acid) in the NB

260 This remained true when neutralizing the IHD-J strain, which lacks a functional version of the fo

261 Of those, IHD developed in 14,155, and MI developed in 6,257.

262 ndard deviation, 2.2 years), 1356 first-time IHD events occurred.

263 sted life-years in 2010 were attributable to IHD deaths.

264 able for 1519 non cases, who were matched to IHD cases by sex and age.

265 intile was observed for mortality related to IHD (HR: 1.70; 95% CI: 1.10, 2.61).

266 servational studies, coffee was unrelated to IHD, and, as expected, childhood cognition.

267 sumption was inversely associated with total IHD (5 studies; 6514 events; RR per 4 weekly 100-g servi

268 onfidence interval, 0.70-0.82, P<0.001) with IHD and 0.95 (95% confidence interval, 0.85-1.07; P=0.43

269 ociated with low-grade inflammation and with IHD, whereas elevated LDL cholesterol is associated caus

270 , ALT levels were negatively associated with IHD (odds ratio (OR) 0.92, 95% confidence interval (CI)

271 ted thyroid function was not associated with IHD (odds ratio (OR) per standard deviation for TSH 1.05

272 al carbon (EC) soot was also associated with IHD mortality (HR = 1.03; 95% CI: 1.00, 1.06 per 0.26-mu

273 and their food sources were associated with IHD mortality in a Chinese population.

274 carbohydrate intake was not associated with IHD mortality risk [men: HR per 5% of energy, 0.97 (95%

275 nsumed was not substantially associated with IHD mortality.

276 d biomass combustion was not associated with IHD mortality.

277 te whether dietary SFAs were associated with IHD risk and whether associations depended on 1) the sub

278 ion and plasma magnesium are associated with IHD risk.

279 Associations with IHD mortality varied by PM2.5 mass constituent and sourc

280 LDL cholesterol is associated causally with IHD without inflammation.

281 between the levels of antibody for CMV with IHD in immunocompetent individuals is uncertain.

282 to assess the associations of ALT (U/L) with IHD, diabetes and other CVD risk factors in the Guangzho

283 to assess the associations of ALT (U/L) with IHD, diabetes and other CVD risk factors.

284 re not associated with CVD incidence or with IHD or stroke (P-trend > 0.11 each).

285 t-line approach in consecutive patients with IHD (n=15).

286 BM from 280 patients with IHD and LV dysfunction were analyzed for cell subsets by

287 roup study was conducted in 66 patients with IHD and LVH, comparing 600 mg/day allopurinol versus pla

288 proves endothelial function in patients with IHD and LVH.

289 hypertrophy (LVH) is common in patients with IHD including normotensive patients.

290 Fifty-three patients with IHD, referred for a first VT ablation to our institution

291 tion in the first procedure in patients with IHD.

292 ge were also protected from rechallenge with IHD-J-Luc or WRvFire VACV without additional treatment.

293 sium excretion had a nonlinear relation with IHD risk (P-curvature = 0.01).

294 Those with IHD, particularly new IHD events, were also more likely

295 ependent cohort of postmenopausal women with IHD, we evaluated associations of the CHS-derived patter

296 ry atherosclerosis progression in women with IHD.

297 fidence interval, 0.85-1.07; P=0.430 without IHD.

298 .30 (1.22 to 1.39) in those with and without IHD, respectively.

299 (IgG) levels in 12,574 participants without IHD from the population-based EPIC-Norfolk cohort, aged

300 cardiac death compared with patients without IHD.